Drug rash with eosinophilia and systemic symptoms to anti-tuberculosis therapy: A retrospective review of inpatients at an academic medical centre in the United States.

Autor: Gutierrez RA; School of Medicine University of California San Francisco California USA., Kazmi M; Department of Dermatology University of California San Francisco California USA., Fox L; Department of Dermatology University of California San Francisco California USA., Shinkai K; Department of Dermatology University of California San Francisco California USA., Arakaki R; Department of Dermatology University of California San Francisco California USA., Dobry A; Department of Dermatology University of California San Francisco California USA., Haemel A; Department of Dermatology University of California San Francisco California USA.
Jazyk: angličtina
Zdroj: Skin health and disease [Skin Health Dis] 2024 Feb 28; Vol. 4 (2), pp. e337. Date of Electronic Publication: 2024 Feb 28 (Print Publication: 2024).
DOI: 10.1002/ski2.337
Abstrakt: This retrospective cohort study analyzes the presentation, diagnosis, and treatment outcomes of patients who developed drug rash with eosinophilia and systemic symptoms (DRESS) to tuberculosis (TB) therapy in a TB non-endemic region. Anti-TB agents represented 7.5% of all antimicrobial-induced DRESS cases, and rifampin was the most commonly implicated agent among drugs used to treat TB.
Competing Interests: Dr. Haemel is a consultant to Guidepoint LLC and to CSL Behring.
(© 2024 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
Databáze: MEDLINE
Externí odkaz: